<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04255597803381</udiDi>
    <basicUdiDi>42555978ANTIBODYAW</basicUdiDi>
    <tradeName>PRAME (QR005)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P003-050</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.580Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803404</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-A004-05</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.533Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803411</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-A004-10</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.505Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803428</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-A004-30</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.478Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803435</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-A004-70</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.450Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803442</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-A004-150</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.425Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803862</udiDi>
    <basicUdiDi>42555978ANTIBODYA0042T</basicUdiDi>
    <tradeName>AMACR (QR108)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-A004-025</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.398Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803893</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P014-01</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.347Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803909</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P014-05</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.330Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803916</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P014-10</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.315Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803923</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-P014-30</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.303Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803930</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-P014-70</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.294Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803947</udiDi>
    <basicUdiDi>42555978ANTIBODYP01467</basicUdiDi>
    <tradeName>PSA (QR038)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-P014-150</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.276Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803961</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N003-01</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.247Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803978</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N003-05</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.232Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803985</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N003-10</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.222Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597803992</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-N003-30</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.208Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804005</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-N003-70</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.198Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804012</udiDi>
    <basicUdiDi>42555978ANTIBODYN0035L</basicUdiDi>
    <tradeName>NKX3.1 (QR055)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P-N003-150</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.181Z</lastUpdated>
  </row>
  <row>
    <udiDi>04255597804104</udiDi>
    <basicUdiDi>42555978ANTIBODYS0066V</basicUdiDi>
    <tradeName>STAT6 (QR041)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-S006-01</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-21T00:04:59.160Z</lastUpdated>
  </row>
</eudamedExport>